[ad_1]
Currently, Olaparib is a treatment intended for women with advanced cancer of the ovaries, fallopian tubes or peritoneum and having a specific genetic mutation
A drug for advanced ovarian cancer is expected to become more "widely available" in Northern Ireland, said the Ministry of Health.
Currently, Olaparib is used to treat women with advanced cancer of the ovary, fallopian tube or peritoneum who have a specific gene mutation – BRCA – and who have undergone at least three cycles of chemotherapy separate.
The drug has been approved for use by the NICE Drug Advisory Body in newly diagnosed cases in England.
- An ovarian cancer drug "for the benefit of new diagnosed"
- "Unacceptable" bad cancer delays in NI patients
In a statement to the BBC, the Ministry of Health said its policy was that patients in Northern Ireland "have the same access to NICE-approved drugs as their counterparts in other parts of the UK" .
"Therefore, the draft NICE guide published today should allow for greater availability of Olaparib in Northern Ireland, where clinically appropriate."
The ministry added that it would take into account the NICE guidelines once they are finalized, which is planned for next month.
"In the meantime, the Health and Social Services Board can order this medication and inform health care providers of the provisions in effect."
Genetic test
Marie-Claire Platt, Head of Public Affairs and Research at Ovarian Cancer Action, said she was "delighted" by this news.
"The postal code lottery for cancer treatment in the four countries has lasted too long and we commend the NI Department for the measures taken to ensure that ovarian cancer patients in Northern Ireland are not left behind. account.
"Genetic testing is essential for women to have access to this treatment, which is why the Ministry of Health must now ensure that all North-Irish women diagnosed with cancer of the world". Ovaries are offered a BRCA screening test at diagnosis. "
Source link
